Amicus Therapeutics (NASDAQ:FOLD) reported quarterly sales of $88.10 million which beat the analyst consensus estimate of $86.29 million by 2.09 percent. This is a 7.23 percent increase over sales of $82.15 million the same period last year.
BMO Capital Downgrades Enbridge to Market Perform, Lowers Price Target to C$55
BMO Capital analyst Ben Pham downgrades Enbridge (TSX:ENB) from Outperform to Market Perform and lowers the price target from C$60 to C$55.
